RecruitingPhase 2Phase 3NCT06474247

Postbiotic as Adjunct Treatment for Vaginal Candidiasis

Use of Postbiotic as Adjunct Treatment for Vaginal Candidiasis in Women

Sponsor

Min-Tze LIONG

Enrollment

118 participants

Start Date

Jun 2, 2024

Study Type

INTERVENTIONAL

Conditions

Vaginal Candidiasis

Summary

This project aims to study the efficacy of intravaginal administration of postbiotic at 1g/day as an adjunct treatment against vaginal candidiasis in women for 4-weeks compared to placebo.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 81 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Placebo and a medical device called Postbiotic for people with vaginal candidiasis. The study is currently recruiting participants at 2 locations. People eligible for this study include women aged 18 Years to 81 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEPostbiotic

Postbiotic at 1g/day as an adjunct treatment against vaginal candidiasis in women for 4-weeks

DEVICEPlacebo

Placebo at 1g/day as an adjunct treatment against vaginal candidiasis in women for 4-weeks

Locations(2)

Sumita Hospital

Lucknow, Aliganj, India

AIMST University

Bedong, Kedah, Malaysia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06474247

Related Trials

Clinical Study of a Vaginal Gel for the Treatment and Prevention of Vaginal Infections

NCT072347861 location

Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes

NCT059086821 location